Ganciclovir Injection, Powder, Lyophilized, For Solution
Product Images NDC 63323-315

7 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ganciclovir (NDC 63323-315). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structures Of Ganciclovir Sodium And Ganciclovir (Gan04 0001 01)

Chemical Structures Of Ganciclovir Sodium And Ganciclovir (Gan04 0001 01)
Chemical structure diagrams of ganciclovir sodium and ganciclovir are shown side by side, each with their respective molecular formulas and molecular weights (277.22 for ganciclovir sodium, 255.23 for ganciclovir).*
FDA Label Image

Figure (Gan04 0001 02)

Figure (Gan04 0001 02)
A line graph titled 'ICM 1653: Time to Progression of CMV Retinitis' showing the proportion without progression over time in days from the start of maintenance therapy. Two lines compare intravenous (IV) and oral routes of administration, with a decreasing trend in proportion without progression up to 150 days.*
FDA Label Image

Figure (Gan04 0001 03)

Figure (Gan04 0001 03)
A line graph titled 'ICM 1774: Time to Progression of CMV Retinitis' showing the proportion of patients without disease progression over time in days from the start of maintenance therapy. It compares intravenous (dashed line) and oral (solid line) administration routes, with the proportion decreasing over 120 days.*
FDA Label Image

Figure (Gan04 0001 04)

Figure (Gan04 0001 04)
A line graph titled 'AVI 034: Time to Progression of CMV Retinitis' showing the proportion without progression over time. The x-axis represents time from start of maintenance therapy in days (0 to 150), and the y-axis shows the proportion without progression (0 to 1). Two lines compare intravenous (IV) and oral administration routes, with IV as a dashed line and oral as a solid line, illustrating progression rates over time.*
FDA Label Image

Premierprorx Logo (Gan04 0001 05)

FDA Label Image

Package Label (PRINCIPAL DISPLAY)

Package Label (PRINCIPAL DISPLAY)
Label for Ganciclovir 500 mg vial for injection, USP, a lyophilized powder for intravenous infusion by Fresenius Kabi USA, LLC. The label includes dosage preparation instructions, storage conditions, a warning about its cytotoxic and carcinogenic potential, and a barcode.*
FDA Label Image

Package Label (PRINCIPAL DISPLAY)

Package Label (PRINCIPAL DISPLAY)
Ganciclovir 500 mg vial for injection, USP, lyophilized powder for solution, by Fresenius Kabi USA, LLC. The label indicates intravenous infusion use only, with a package of 25 x 10 mL vials. Warning notes highlight its potency as a cytotoxic agent and suspected carcinogen. Preparation instructions specify reconstitution with sterile water for injection into a clear solution for IV use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.